SLC5A2 and type 2 diabetes mellitus: Several SGLT2 inhibitors have been developed, including canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, and some have been approved in various regions for the treatment of type 2 diabetes (e.g., canagliflozin in the US, dapagliflozin in Europe, and ipragliflozin in Japan).